RGNX

Regenxbio Inc. is Buy-rated, with upcoming ATMOSPHERE and ASCENT readouts and RGX-202 regulatory milestones as key near-term catalysts. RGNX faces a structural revenue headwind from ZOLGENSMA royalty expiration, with new assets like ITVISMA and external funding supporting liquidity. Pivotal wet AMD Phase III data for sura-vec in 4Q26 and an RGX-202 BLA submission in 1Q27 are critical for future valuation.

REGENXBIO NASDAQ: RGNX is approaching pivotal trial results for its eye disease gene therapy and preparing a U.S. application for its Duchenne muscular dystrophy treatment, executives said during the company's third-quarter earnings call.

REGENXBIO Inc. (RGNX) Q3 2026 Earnings Call Transcript

Regenxbio (RGNX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $1.35. This compares to a loss of $1.2 per share a year ago.

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027 Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE ® and ASCENT ® , expected in Q4 2026 Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing Webcast today at 8:00 a.m. ET ROCKVILLE, Md.

The average of price targets set by Wall Street analysts indicates a potential upside of 214.6% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.

ROCKVILLE, Md., Nov. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Stifel 2026 Healthcare Conference.

Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ROCKVILLE, Md., Oct. 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 5, at 8:00 a.m.